- Home
- TLRY vs SPRY Comparison
TLRY vs SPRY Comparison
Compare TLRY & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | SPRY |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.9M | 788.5M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TLRY | SPRY |
|---|---|---|
| Price | $5.51 | $9.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $72.33 | $40.00 |
| AVG Volume (30 Days) | ★ 3.5M | 1.7M |
| Earning Date | 04-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $8.79 | $87.40 |
| Revenue Next Year | $19.98 | $81.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $6.66 |
| 52 Week High | $15.70 | $18.63 |
Technical Indicators
Market Signals| Indicator | TLRY | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 42.97 | 60.67 |
| Support Level | $5.09 | $7.82 |
| Resistance Level | $7.01 | $9.51 |
| Average True Range (ATR) | 0.21 | 0.61 |
| MACD | 0.06 | 0.14 |
| Stochastic Oscillator | 68.95 | 74.31 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.